fecal microbiota transfer

DRUG3 trials

Sponsors

MaaT Pharma, Michael Dill

Conditions

Fecal Microbiota TransplantationHCC - Hepatocellular CarcinomaImmunotherapyIntensive Care Units

Phase 2

Evaluation of Heterologous Fecal microbiotA Transfer in ICU Patients: a FeasibilitY and SafetY StudY

TerminatedNCT03350178

MaaT PharmaFecal Microbiota Transplantation, Intensive Care Units

Start: 2018-01-15End: 2019-02-19Updated: 2019-03-08

Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSfer

CompletedNCT03359980

MaaT PharmaFecal Microbiota Transplantation

Start: 2018-08-13End: 2020-11-26Updated: 2021-02-23

Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)

RecruitingNCT05690048

Michael DillHCC - Hepatocellular Carcinoma, Immunotherapy

Start: 2025-07-16End: 2028-03-31Target: 48Updated: 2025-08-06

Related Papers

Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab – a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial)

BMJ Open2025-09-012 citations

Pooled allogeneic faecal microbiota MaaT013 for steroid-resistant gastrointestinal acute graft-versus-host disease: a single-arm, multicentre phase 2 trial.

2023-07-2627 citations

Pooled Allogenic Fecal Microbiotherapy MaaT013 for the Treatment of Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Phase IIa Heracles Study and Expanded Access Program

Blood2021-11-057 citations

Dietary Therapy in Conjunction With Immunosuppression to Treat Gastrointestinal Graft‐versus‐host Disease (GVHD)

Journal of Pediatric Gastroenterology and Nutrition2019-06-224 citations